Category: Abiomed Inc.Syndicate content

Abiomed jumps on FDA deal for Impella indication

October 30, 2014 by Brad Perriello

Abiomed says it's come to an agreement with the FDA on an indication for its flagship Impella 2.5 heart pump, and now expects to win pre-market approval early next year without a hearing before an FDA advisory panel.

Abiomed jumps on deal with FDA

Medtronic taps Brigham & Women's prez Nabel for board | Personnel Moves

September 18, 2014 by Brad Perriello

Medtronic taps Dr. Elizabeth Nabel, president of Brigham & Women's Faulkner Hospital in Boston, for a seat on its board of directors.

Medtronic taps Brigham & Women's prez Nabel for board | Personnel Moves

Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup

September 17, 2014 by Arezu Sarvestani

Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.

TCT 2014 Roundup

Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.

Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abiomed inks extension in Impella probe

August 12, 2014 by Brad Perriello

Abiomed says it struck a deal to extend the statute of limitations on any charges that might arise from a U.S. Justice Dept. probe of the marketing for its Impella heart pump and raised its estimate of the legal fees from the investigation.

Abiomed inks extenstion in Impella probe

Abiomed (NSDQ:ABMD) said it struck a deal with federal prosecutors to extend the tolling agreement on a probe of its marketing of its flagship Impella heart pump.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abiomed expects FDA nod for Impella sooner than forecast

July 31, 2014 by Brad Perriello

Abiomed said today that it expects the FDA to grant the pre-market approval application for its flagship Impella heart pump sooner rather than later, pushing up the timeline to March 2015.

Abiomed expects FDA nod for Impella sooner than forecast

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abiomed acquires German heart pump maker ECP

July 2, 2014 by Brad Perriello

Abiomed says it acquired German heart pump maker ECP Entwicklungsgesellschaft in a deal worth up to $30 million, including milestones.

Abiomed acquires German heart pump maker ECP

Abiomed (NSDQ:ABMD) said yesterday that it acquired a German heart pump maker in a deal worth up to $30 million.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp